Your session is about to expire
← Back to Search
Other
Lu AG06466 for Post-Traumatic Stress Disorder
Phase 1
Waitlist Available
Research Sponsored by H. Lundbeck A/S
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 12-13
Summary
This trial is testing a new medication called Lu AG06466 to see if it helps people with PTSD. Participants will receive the medication at different times. The goal is to find out if repeated doses of Lu AG06466 can improve PTSD symptoms.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 12-13
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 12-13
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Behavioural Measures During fMRI Tasks
Behavioural Measures During the Threat Processing Task
Functional Magnetic Resonance Imaging (fMRI) Data: Mean Blood Oxygen Level Dependent (BOLD) Percent Signal Change During Card Guessing Task
+8 moreTrial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Lu AG06466Experimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Lu AG06466
2020
Completed Phase 1
~90
Find a Location
Who is running the clinical trial?
H. Lundbeck A/SLead Sponsor
329 Previous Clinical Trials
77,674 Total Patients Enrolled
Email contact via H. Lundbeck A/SStudy DirectorLundbeckClinicalTrials@Lundbeck.com
189 Previous Clinical Trials
58,294 Total Patients Enrolled
Other Trials to Consider
Popular Categories
Learn More About These Treatments
Share this study with friends
Copy Link
Messenger